HK1212628A1 - Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5 - Google Patents
Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5Info
- Publication number
- HK1212628A1 HK1212628A1 HK16100682.5A HK16100682A HK1212628A1 HK 1212628 A1 HK1212628 A1 HK 1212628A1 HK 16100682 A HK16100682 A HK 16100682A HK 1212628 A1 HK1212628 A1 HK 1212628A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cxcl11
- cxcl13
- cxcl9
- cxcr5
- cxcl10
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/044464 WO2014003742A1 (en) | 2012-06-27 | 2012-06-27 | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1212628A1 true HK1212628A1 (en) | 2016-06-17 |
Family
ID=49783685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16100682.5A HK1212628A1 (en) | 2012-06-27 | 2016-01-21 | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2866830A4 (en) |
| JP (1) | JP2015524793A (en) |
| CN (2) | CN112807427A (en) |
| HK (1) | HK1212628A1 (en) |
| WO (1) | WO2014003742A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10413605B2 (en) | 2014-04-08 | 2019-09-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Combination therapy for the treatment of autoimmune diseases |
| CN105039319A (en) * | 2015-06-22 | 2015-11-11 | 浙江理工大学 | Biomarker for forecasting new auxiliary chemotherapy curative effect of breast cancer and fluorescence quantitative immune PCR kit |
| MX2018016364A (en) | 2016-06-20 | 2019-11-28 | Kymab Ltd | Anti-pd-l1 antibodies. |
| CN107236023B (en) * | 2017-05-12 | 2021-05-07 | 苏州创澜生物科技有限公司 | Antigen composition for detecting tuberculosis infection and application thereof |
| JP6994726B2 (en) * | 2017-11-24 | 2022-02-04 | ソウル大学校産学協力団 | Anti-inflammatory composition containing graphene nanostructures |
| CN110511912B (en) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | Functional modulation of immune cells |
| CN109777784B (en) * | 2019-02-22 | 2021-12-31 | 上海尚泰生物技术有限公司 | Construction method and application of chimeric antigen receptor vector for enhancing migration to tumor part |
| AU2020325285A1 (en) * | 2019-08-07 | 2022-02-03 | Edifice Health, Inc. | Treatment of prevention of cardiovascular disease |
| EP3960861A1 (en) * | 2020-08-31 | 2022-03-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers that target cxcl9 |
| CN114432502B (en) * | 2021-12-31 | 2023-02-03 | 中山大学附属第八医院（深圳福田） | Hydrogel loaded with OP3-4 polypeptide and anti-CXCL 9 antibody, and preparation method and application thereof |
| WO2023192911A2 (en) * | 2022-03-30 | 2023-10-05 | Flagship Pioneering Innovations V, Inc. | Cxcl-modulating compositions and methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4502408B2 (en) * | 1996-09-10 | 2010-07-14 | テオドーア−コッヒャー インスティトゥーテ | CXCR3 chemokine receptor, antibody, nucleic acid and method of use |
| US7964194B2 (en) * | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
| RU2015147300A (en) * | 2007-08-29 | 2019-01-11 | Санофи-Авентис | HUMANIZED ANTIBODIES TO CXCR5, THEIR DERIVATIVES AND THEIR APPLICATION |
| CN103347896B (en) * | 2010-09-02 | 2017-06-13 | 瓦西尼斯公司 | Anti-cxcl 13 antibodies and its application method |
| CN103608680A (en) * | 2010-12-14 | 2014-02-26 | 詹姆士·W·里拉尔德 | Use of anti-CXCL13 and anti-CXCR5 antibodies for treatment or detection of cancer |
-
2012
- 2012-06-27 CN CN201710770034.2A patent/CN112807427A/en active Pending
- 2012-06-27 CN CN201280075412.0A patent/CN104870013A/en active Pending
- 2012-06-27 EP EP12880044.8A patent/EP2866830A4/en not_active Withdrawn
- 2012-06-27 WO PCT/US2012/044464 patent/WO2014003742A1/en active Application Filing
- 2012-06-27 JP JP2015520137A patent/JP2015524793A/en active Pending
-
2016
- 2016-01-21 HK HK16100682.5A patent/HK1212628A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104870013A (en) | 2015-08-26 |
| EP2866830A4 (en) | 2015-12-09 |
| WO2014003742A1 (en) | 2014-01-03 |
| CN112807427A (en) | 2021-05-18 |
| JP2015524793A (en) | 2015-08-27 |
| EP2866830A1 (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212628A1 (en) | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5 | |
| HK1214259A1 (en) | Etp derivatives etp | |
| SI2920149T1 (en) | 3-aminocycloalkyl compounds as ror-gamma-t inhibitors and uses thereof | |
| GB2508204B (en) | Orthosis | |
| HK1207078A1 (en) | Inhibition of enzymes | |
| EP2895609A4 (en) | Methods and compostions for the specific inhibition of myc by double-stranded rna | |
| ZA201402475B (en) | Self-adhesive lavatory treatment compositions | |
| EP2675469A4 (en) | Compositions, devices and methods of use thereof for the treatment of cancers | |
| HK1212625A1 (en) | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5 | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| EP2906255A4 (en) | Antisense compounds and uses thereof | |
| EP2858648A4 (en) | Methods and compositions for the inhibition of pin1 | |
| EP2828241A4 (en) | Compositions and methods for inhibition of cathepsins | |
| EP2897689A4 (en) | Systems, compositions and methods for the treatment of alopecia | |
| IL236138A0 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| EP2869821A4 (en) | Compositions and methods for treating and inhibiting viral infections | |
| HK1209639A1 (en) | Gpbp-1 inhibition and its therapeutic use gpbp-1 | |
| LT2858606T (en) | Orthosis | |
| HK1201066A1 (en) | Pyranopyridone inhibitors of tankyrase | |
| EP2931746A4 (en) | Methods and compositions for the specific inhibition of ckap5 by double-stranded rna | |
| EP2688901A4 (en) | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 | |
| EP2931280A4 (en) | Methods and compositions for inhibiting cnksr1 | |
| HK1205500A1 (en) | Kinase inhibitors for the treatment of cancer | |
| EP2800568A4 (en) | Compositions, methods of use, and methods of treatment |